Electrophysiologic profile and efficacy of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with sustained monomorphic ventricular tachycardia☆
References (21)
Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE Study)
Am J Cardiol
(1993)- et al.
Clinical and electrophysiologic effects of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with angina pectoris
Am J Cardiol
(1992) - et al.
Measurements of the class III antidysrhythmic drug UK-68,698 in plasma by radioimmunoassay
J Pharm Biomed Anal
(1991) - et al.
Effect of flecainide acetate on prevention of electrical induction of ventricular tachycardia and occurence of ischemic ventricular fibrillation during the early postmyocardial infarction period: evaluation in a conscious canine model of sudden death
J Am Coll Cardiol
(1987) - et al.
Drug therapy for ventricular tachyarrhythmias: how many electropharmacologic trials are appropriate?
J Am Coll Cardiol
(1991) - et al.
Effects of the class III antiarrhythmic drug dofetilide on ventricular monophasic action potential duration and QT interval dispersion in stable angina pectoris
Am J Cardiol
(1992) - et al.
Effects of UK-68,798, a novel class III antiarrhythmic agent, in conscious dogs (abstr)
J Mol Cell Cardiol
(1989) A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias
N Engl J Med
(1993)Preliminary report, effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction
N Engl J Med
(1989)- et al.
Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: a meta-analysis of randomized, controlled trials
Circulation
(1990)
Cited by (55)
Antiarrhythmic agents and torsades de pointes
2022, Torsades de PointesPause-dependent polymorphic ventricular tachycardia during long-term treatment with dofetilide: A placebo-controlled, implantable cardioverter-defibrillator-based evaluation
2001, Journal of the American College of CardiologyCitation Excerpt :The latter finding suggests that dofetilide may reduce the number of recurrences of this type of VT. This is consistent with previous experimental (30,31)and clinical (18,19)studies, which showed that dofetilide reduced the inducibility rate of sustained MVT. Such an effect on MVT is consistent with an increase in wavelength of the reentry circuit due to lengthening of tissue refractoriness (32).
Dofetilide: Is the treatment worse than the disease?
2001, Journal of the American College of CardiologyCitation Excerpt :In addition, dofetilide treatment was associated with a significantly increased rate of successful antitachycardia pacing in ICD patients. These data are consistent with two small studies showing dofetilide was also effective in acutely suppressing inducible sustained ventricular tachycardia during serial electrophysiologic testing in approximately 45% of patients (25,26). Under the protective cover of an ICD device, electrophysiologists and cardiologists may be more accepting of potential rare episodes of ventricular proarrhythmia, as long as the antiarrhythmic effects of the dofetilide prove beneficial.
Role of dofetilide in patients with ventricular arrhythmias
2024, Journal of Interventional Cardiac ElectrophysiologyOverview of Cardiac Arrhythmias and Treatment Strategies
2023, Pharmaceuticals
- ☆
This study was supported in part by a grant from Pfizer Central Research, Sandwich, Kent, United Kingdom.